Mivebresib（ABBV-075）

Mivebresib is a potent and orally available bromodomain and extraterminal domain (BET) bromodomain inhibitor.
CAS：1445993-26-9
分子式：C22H19F2N3O4S
分子量：459.47
纯度：98%
存储：Store at -20°C

Background:

Mivebresib is a potent and orally available bromodomain and extraterminal domain (BET) bromodomain inhibitor. Mivebresib binds to BRD4 with a Ki of 1.5 nM.

Mivebresib inhibit DHT-stimulated transcription of AR target genes without significant effect on AR protein expression. In addition to blocking the transcription activation downstream of AR, Mivebresib is also a potent inhibitor of MYC and the TMPRSS2-ETS fusion proteins[1].

参考文献:
[1]. EJ Faivre et al. Abstract 4694: ABBV-075, a novel BET family inhibitor, disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo